Brief: NextCell Pharma Q3 Operating Loss Widens To SEK 9.3 Mln
28/07/2022 06:40
July 28 (Reuters) - NextCell Pharma AB NXTCL.ST :
* PUBLISHES INTERIM REPORT 3 2021/2022
* Q3 OPERATING LOSS SEK 9.3 MILLION VERSUS LOSS SEK 6.5
MILLION
YEAR AGO
* Q3 OPERATING INCOME SEK 1,636 THOUSAND VERSUS SEK 906
THOUSAND
YEAR AGO
Source text for Eikon: ID:nWkrq1TXn
Further company coverage: NXTCL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on NextCell Pharma AB
See all newsBrief: NextCell Pharma Q1 Operating Income At SEK 2.8 Million
Brief: Nextcell Pharma Q4 Operating Income SEK 1.8 Mln
Brief: Nextcell Pharma Says ProTrans Data Show Insulin Production Preservation
Brief: NextCell Board Proposes Directed Issue Of 15,000,000 Shares
Brief: Nextcell Decides To Propose Directed Share Issue Of SEK 15 Mln